Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma

DH Broide, G Stachnick, D Castaneda, J Nayar… - Journal of clinical …, 2001 - Springer
DH Broide, G Stachnick, D Castaneda, J Nayar, M Miller, JY Cho, M Roman, J Zubeldia
Journal of clinical immunology, 2001Springer
This study investigated whether immunostimulatory DNA sequences (ISS) induce a transient
or sustained inhibition of Th2 responses to inhaled antigen. We sensitized mice with
subcutaneous injections to develop a Th2 response to ovalbumin (ova) and then
administered a dose of ISS prior to ova inhalation challenge. Mice were then rechallenged
with ova by inhalation a second time at varying time points after the first ova inhalation (1 to
8 weeks later) to determine whether the ISS dose administered prior to the first ova …
Abstract
This study investigated whether immunostimulatory DNA sequences (ISS) induce a transient or sustained inhibition of Th2 responses to inhaled antigen. We sensitized mice with subcutaneous injections to develop a Th2 response to ovalbumin (ova) and then administered a dose of ISS prior to ova inhalation challenge. Mice were then rechallenged with ova by inhalation a second time at varying time points after the first ova inhalation (1 to 8 weeks later) to determine whether the ISS dose administered prior to the first ova inhalation protected against a subsequent second ova inhalation challenge. A single dose of ISS inhibited the Th2 response to the first inhalation of ova antigen, as well as 4 weeks later to the second inhalation of ova. However, ISS did not inhibit a Th2 response to the second inhalation of ova 8 weeks later. The reversible inhibition of Th2 responses at 8 weeks suggests the need for repeated ISS administration at monthly intervals.
Springer